...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What if...?
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Fouremm,

I thought the RVX royalty preferred shares were set at the time of the spinout = 75+ million, no? Just the Zenith shares would get diluted, right?

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply